"Designing Growth Strategies is in our DNA"

Familial Amyloid Polyneuropathy Therapeutics Market Size, Share & Industry Analysis By Drug Type (Inotersen, Tafamidis, Patisiran, Others), By Disease Type (Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III), Familial Amyloid Polyneuropathy-IV (FAP-IV)), By Gender Type (Male, Female), By Distribution Channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies) Others and Regional Forecast, 2024-2032

Region :Global | Report ID: FBI102086 | Status : Ongoing

 

KEY MARKET INSIGHTS

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid polyneuropathy, is an inherited, progressive and a rare disease caused by the unusual deposits of amyloids or proteins around peripheral nerves and other tissues. FAP is considered to be very rare in most countries of the world. The incidence rate of the disease is estimated to be comapratively lower in developed countries such as the U.S. and several other European countries. In other regions of the world, the prevalence is comparatively higher.


Up Arrow

Key Market Driver -

Rise in number of R&D activities pertaining to enhanced treatment solutions for familial amyloid polyneuropathy

Down Arrow

Key Market Restraint -

Stringent government regulations for approval of such drugs


The familial amyloid polyneuropathy therapeutics market is estimated to witness substantial growth across the forecast period. High growth is attributable to increasing number of therapeutic drugs being approved for the treatment of the disease. Moreover, rising incidence of familial amyloid polyneuropathy disorder across various countries of the world is another major factor augmenting market growth. Additionally, increasing adoption rate of therapeutic drugs for treatment of the disease, owing to rising awarness among the population of emerging countries such as India, China and others will create new opportunities for the familial amyloid polyneuropathy market. Also, increasing number of companies operating in the market will further provide lucrative growth opportunities. Hence, the aforementioned factors will reflect a positive growth trajectory for the familial amyloid polyneuropathy therapeutics market across the forecast period.

However, high cost associated with the research & development and treatment activities might restrict market growth up to a certain extent. Also, stringent government norms related to approval of such drugs is another chief factor limiting market growth.

Market Segmentation:


By drug type, the market is segmented into inotersen, tafamidis, patisiran and others. Based on disease type, the market is segmented into Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III) and Familial Amyloid Polyneuropathy-IV (FAP-IV). Based on gender type, the familial amyloid polyneuropathy therapeutics market is bifurcated into male and female. Furthermore, the distribution channel is classified as hospital pharmacies, retail pharmacies and online pharmacies.

From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Players Covered:


The major companies in the global familial amyloid polyneuropathy therapeutics market report includes Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc., and others.   

Key Insights



  • Product Pipeline of the Therapeutic Drugs for Familial Amyloid Polyneuropathy

  • Prevalence Ratio of Familial Amyloid Polyneuropathy, Key Countries, 2018

  • New Product Launch, Key Players  

  • Product Approvals and Clinical Trial stage Data


Regional Analysis:


The global familial amyloid polyneuropathy therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is estimated to witness lucrative growth across the forecast period. High growth is attributed to increasing prevalence of familial amyloid polyneuropathy disorder across various countries of the Asia Pacific regions. North America, followed by Europe is expected to hold substantial amount of shares across 2018 to 2026, owing to growing number of market players operating in the regions.

To gain extensive insights into the market, Request for Customization


Moreover, Latin America and Middle East & Africa are projected to register a comparatively higher CAGR by the end of the forecast period, due to growing awareness among the population about the various benefits associated with familial amyloid polyneuropathy therapeutics, coupled with growing adoption rate of the drugs in these countries.

Segmentation






























 ATTRIBUTE

 DETAILS

By Drug Type



  • Inotersen

  • Tafamidis

  • Patisiran

  • Others



By Disease Type



  • Familial Amyloid Polyneuropathy-I (FAP-I)

  • Familial Amyloid Polyneuropathy-II (FAP-II)

  • Familial Amyloid Polyneuropathy-III (FAP-III)

  • Familial Amyloid Polyneuropathy-IV (FAP-IV)



By Gender Type



  • Male

  • Female



By Distribution Channel



  • Hospital Pharmacies

  • Retail pharmacies

  • Online Pharmacies



By Geography



  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



 Familial Amyloid Polyneuropathy Therapeutics Industry Developments



  • In July 2019, Alnylam Pharmaceuticals Inc., announced the Health Canada approval and immediate availability of ONPATTRO (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Such approvals allow the company to cover untapped markets, thus augmenting revenue growth.

  • In August 2017, Pfizer Inc. announced the successful analysis results of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with hereditary amyloid polyneuropathy and was well tolerated, with no unexpected side effects. Such approvals enabled the company to generate more revenue.





  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Pfizer
abbvie
Siemens Healthineers
Jubilant
uniliver

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X